Skip to main content
Premium Trial:

Request an Annual Quote

Genmab Licenses Angiogenesis Targets from Bionomics

NEW YORK, Feb. 14 (GenomeWeb News) - Genmab said today that it has licensed exclusive worldwide rights to develop therapeutics based upon a series of angiogenesis targets identified by Bionomics.


Under the agreement, Copenhagen, Denmark-based Genmab has acquired the rights to eight proteins identified and characterized by Bionomics using its Angene angiogenesis platform.


Bionomics will receive an upfront fee and additional fees upon the completion of preclinical and clinical milestones, the companies said. Bionomics will also receive milestone payments and royalties on product sales.

The Scan

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.

Fragile X Syndrome Mutations Found With Comprehensive Testing Method

Researchers in Clinical Chemistry found fragile X syndrome expansions and other FMR1 mutations with ties to the intellectual disability condition using a long-range PCR and long-read sequencing approach.

Team Presents Strategy for Speedy Species Detection in Metagenomic Sequence Data

A computational approach presented in PLOS Computational Biology produced fewer false-positive species identifications in simulated and authentic metagenomic sequences.

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.